| Market Cap | 25.30B | P/E | 3.70 | EPS this Y | -165.90% | Ern Qtrly Grth | - |
| Income | -504.4M | Forward P/E | 26.58 | EPS next Y | -25.60% | 50D Avg Chg | -3.00% |
| Sales | 2.69B | PEG | 1.13 | EPS past 5Y | -35.56% | 200D Avg Chg | -20.00% |
| Dividend | N/A | Price/Book | 1.25 | EPS next 5Y | -35.11% | 52W High Chg | -44.00% |
| Recommedations | 2.20 | Quick Ratio | 7.25 | Shares Outstanding | 237.77M | 52W Low Chg | 5.00% |
| Insider Own | 62.82% | ROA | -2.21% | Shares Float | 86.97M | Beta | 0.23 |
| Inst Own | 18.92% | ROE | -2.59% | Shares Shorted/Prior | 2.68M/3.09M | Price | 104.98 |
| Gross Margin | 82.91% | Profit Margin | -18.75% | Avg. Volume | 689,574 | Target Price | 125.00 |
| Oper. Margin | -747.32% | Earnings Date | Nov 4 | Volume | 591,875 | Change | -2.01% |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
| Morgan Stanley | Overweight | Sep 24, 24 |
| Deutsche Bank | Buy | Sep 19, 24 |
| UBS | Neutral | Sep 18, 24 |
| Jefferies | Buy | Sep 17, 24 |
| JP Morgan | Neutral | Sep 16, 24 |
| B of A Securities | Buy | Sep 16, 24 |
| HC Wainwright & Co. | Buy | Sep 16, 24 |
| Jefferies | Hold | Sep 13, 24 |
| HC Wainwright & Co. | Buy | Aug 27, 24 |